drugset

drugset / Trial / NCT00093873

Study Evaluating AMG 706 in Subjects With Advanced Solid Tumors

NCT00093873 ↗

Phase 1 Completed 71 enrolled Amgen

Non-randomizedSingle-groupOpen-labelTreatment

Summary

This study will determine the safety and pharmacokinetics of AMG 706 in subjects with advanced solid tumors.

Timeline

Start: 2003-07
Primary completion: 2006-02
Completion: 2006-12

Publications

Results Rosen LS, Kurzrock R, Mulay M, Van Vugt A, Purdom M, Ng C, Silverman J, Koutsoukos A, Sun YN, Bass MB, Xu RY, Polverino A, Wiezorek JS, Chang DD, Benjamin R, Herbst RS. Safety, pharmacokinetics, and efficacy of AMG 706, an oral multikinase inhibitor, in patients with advanced solid tumors. J Clin Oncol. 2007 Jun 10;25(17):2369-76. doi: 10.1200/JCO.2006.07.8170.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	motesanib	Small molecule	25 mg	Oral
Subject	motesanib	Small molecule	50 mg	Oral
Subject	motesanib	Small molecule	125 mg	Oral
Subject	motesanib	Small molecule	175 mg	Oral

Indications